3B India Q2 exports rise 32% despite geopolitical disruption

3B BlackBio Dx Ltd., referred to as 3B India, recorded Rs 6.57 crore in Q2 2026/27 export sales, 32% above Rs 4.98 crore in Q2 2025/26, despite delayed and cancelled orders linked to geopolitical tensions and logistics constraints. 3B India said it operates across more than 70 countries and serves more than 200 customers.

How fast did 3B India’s Q2 export business grow?

3B India’s export sales rose 32% year on year to Rs 6.57 crore in Q2 2026/27 from Rs 4.98 crore in Q2 2025/26. Management said the growth would have been slightly higher under more favourable geopolitical conditions. This Q2 comparison is the presentation’s current-period measure of overseas diagnostic sales.

The longer first-half trend also shows export sales increasing in every reported period, from Rs 3.62 crore in H1 2023 to Rs 12.54 crore in H1 2026. Management reported a compound annual growth rate, or CAGR, of 51.3% for this series. H1 2026 sales exceeded H1 2025, while the increase from H1 2024 to H1 2025 was also recorded despite a smaller absolute rise than in the preceding period.

The reported H1 series reached its highest level in H1 2026, following Rs 7.20 crore in H1 2024 and Rs 9.29 crore in H1 2025. The source does not provide a Q1 2026/27 export figure, so it does not establish the contribution of either quarter to the Rs 12.54 crore H1 total. It does establish that Q2 sales grew 32% even as some shipments were disrupted.

What disrupted 3B India’s export orders in Q2?

Geopolitical tensions delayed or cancelled some 3B India orders in Q2 2026/27, while challenging logistics delayed supplies. Management directly linked these factors to export growth that it said could otherwise have been slightly higher. The presentation does not disclose the value of cancelled orders, affected countries or the number of customers involved.

The disruption occurred alongside international commercial activity in Europe, Africa and Asia-Pacific, or APAC. 3B India said it added customers in existing and new markets, completed product registrations in several countries and continued registrations elsewhere. It also reported annual rate contracts in the Middle East, Southeast Asia and Europe, without giving contract values or the timing of associated revenue.

New-territory entry depends on regulatory clearance and can take approximately 10 to 15 months after registrations are initiated, according to 3B India. The company has initiated registrations in some Latin American, or LATAM, and Southeast Asian countries, and management expects commercial orders from them in the near future. No completion date, expected order value or forecast sales contribution was provided.

Where is 3B India expanding its international reach?

3B India is present in more than 70 countries across Europe, the Middle East, APAC, LATAM and North America, while Africa is being developed through strategic channel-partner relationships. The company reported more than 200 customers and said it added a few countries after registration and tendering processes. That sequence makes regulatory approval and procurement progress material to new-market sales.

Management said 3B India appointed new channel partners and was in advanced discussions with leading international distributors for new projects. It also cited strong Middle East order inflow and targeted marketing in untapped markets. However, the presentation gives no geographic sales split, so it does not identify which region contributed most to Q2 2026/27 export sales of Rs 6.57 crore.

The marketing calendar includes Medica in Düsseldorf from 16 to 19 November 2026 and WHX Labs in Dubai from 25 to 28 January 2027. 3B India also participated in WHX Johannesburg from 6 to 8 October 2026 alongside Coris BioConcept. Management expects tangible financial outcomes from the Johannesburg event within the current fiscal year, but did not disclose signed business from the event.

How is TRUPCR Europe contributing to overseas growth?

TRUPCR Europe Limited, or TPE, recorded Q2 2026/27 sales of GBP 536,707, up 27.6% from GBP 420,435 in Q2 2025/26. H1 2026/27 sales were GBP 969,704, a 21.1% increase from GBP 800,912 in H1 2025/26. The reported Q2 growth rate was therefore 6.5 percentage points above the H1 rate.

Management described TPE’s Made in UK portfolio as gaining steady acceptance across Europe and cited EU-aligned branding and smoother logistics as supporting its European footprint. TPE is also entering LATAM, Africa and other priority markets, according to the presentation. Its Manchester site holds ISO 13485:2016 certification from BSI in the UK, which management said supports regulatory compliance and faster market access.

TPE’s stated plan includes global exhibitions, onboarding new distributors and expanding its marketing team. These measures align with 3B India’s wider programme of channel-partner appointments, product registrations and targeted market entry across more than 70 countries. The presentation does not disclose TPE profitability, its share of group exports or the portion of international sales supplied from Manchester.

Conclusion

The reported figures show export expansion across 3B India’s direct international markets and its Manchester-based TPE operation, even though Q2 2026/27 logistics and geopolitical conditions interrupted some orders. The H1 export series rose from Rs 3.62 crore in H1 2023 to Rs 12.54 crore in H1 2026, while TPE reported 27.6% Q2 sales growth in GBP terms.

The next disclosed milestones are the 10-to-15-month registration process in selected LATAM and Southeast Asian markets, where management expects commercial orders in the near future, and Medica in November 2026 and WHX Labs in January 2027. The presentation also leaves unresolved whether geopolitical tensions, delayed supplies and cancelled orders will continue to affect export conversion.